CEFAZOLIN FOR INJECTION POWDER FOR SOLUTION

Страна: Канада

Език: английски

Източник: Health Canada

Активна съставка:

CEFAZOLIN (CEFAZOLIN SODIUM)

Предлага се от:

TEVA CANADA LIMITED

АТС код:

J01DB04

INN (Международно Name):

CEFAZOLIN

дозиране:

10G

Лекарствена форма:

POWDER FOR SOLUTION

Композиция:

CEFAZOLIN (CEFAZOLIN SODIUM) 10G

Начин на приложение:

INTRAVENOUS

Броя в опаковка:

1

Вид предписание :

Prescription

Терапевтична област:

FIRST GENERATION CEPHALOSPORINS

Каталог на резюме:

Active ingredient group (AIG) number: 0109442003; AHFS:

Статус Оторизация:

APPROVED

Дата Оторизация:

2013-04-12

Данни за продукта

_Pr_
_CEFAZOLIN FOR INJECTION Product Monograph Page 1 of 21 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
CEFAZOLIN FOR INJECTION
POWDER FOR SOLUTION, 500 MG, 1.0 G AND 10.0 G, CEFAZOLIN (AS CEFAZOLIN
SODIUM) PER VIAL
Intravenous, Intramuscular
USP
Antibiotic
Teva Canada Limited
Date of Initial Authorization:
30 Novopharm Court
January 19, 1995
Toronto, Ontario
M1B 2K9
Date of Revision:
Canada
MAR 15, 2024
www.tevacanada.com
Submission Control Number: 265641
_Pr_
_CEFAZOLIN FOR INJECTION (Cefazolin Sodium) Product Monograph Page 2
of 21 _
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS
11/2020
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.....................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
1 INDICATIONS
..........................................................................................................................
3
2 CONTRAINDICATIONS
.........................................................................................................
4
4
DOSAGE AND ADMINISTRATION
......................................................................................
4
4.2 Recommended Dose and Dosage Adjustment
......................................................................
4
4.3 Reconstitution
.......................................................................................................................
6
4.4 Administration
......................................................................................................................
8
5 OVERDOSAGE
.........................................................................................................................
8
6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKA